Expression and phosphorylation of protein kinase C isoforms in Aβ1-42 activated T lymphocytes from Alzheimer's disease

International Journal of Immunopathology and Pharmacology

Volumn 21, Issue 1, 2008, Pages 23-33

  Ciccocioppo, F ^a   Lanuti, P ^a   Marchisio, M ^a   Gambi, F ^a   Santavenere, E ^a   Pierdomenico, L ^a   Bascelli, A ^a   Velluto, L ^a   Gambi, D ^a   Miscia, Sebastiano ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Alzheimer's disease; Amyloid 1 42; Protein kinase C; T cell activation

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; PROTEIN KINASE C ALPHA; PROTEIN KINASE C DELTA; PROTEIN KINASE C ZETA;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION;

EID: 41849102013     PISSN: 03946320     EISSN: None     Source Type: Journal    
DOI: 10.1177/039463200802100104     Document Type: Article

References (41)

1. Fratiglioni L., L.J. Launer, K. Andersen, M.M. Breteler, J.R. Copeland, J.F. Dartigues, A. Lobo, J. Martinez-Lage, H. Soininen and A. Hofman. 2000. Incidence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 54(S):10.
2. Selkoe D.J. 2001. Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81:741.
3. Urbanc B., L. Cruz, R. Le, J. Sanders, K.H. Ashe, K. Duff, H.E. Stanley, M.C. Irizarry and B.T. Hyman. 2002. Neurotoxic effects of thioflavin S-positive amyloid deposits in transgenic mice and Alzheimer's disease. Proc. Natl. Acad. Sci. USA 99: 13990.
4. Jarrett J.T. and P.T. Lansbury Jr. 1993. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055.
5. Licastro F., M. Chiappelli, M. Ruscica, V. Carnelli and M.M. Corsi. 2005. Altered cytokine and acute phase response protein levels in the blood of children with Downs syndrome: relationship with dementia of Alzheimer's type. Int. J. Immunopathol. Pharmacol. 18:165.
6. Cooper N.R., R.N. Kalaria, P.L. McGeer and J. Rogers. 2000. Key issues in Alzheimer's disease inflammation. Neurobiol. Aging 2:451.
7. Haas J., B. Storch-Hagenlocher, A. Biessmann and B. Wildemann. 2002. Inducible nitric oxide synthase and argininosuccinate synthetase: co-induction in brain tissue of patients with Alzheimer's dementia and following stimulation with beta-amyloid 1-42 in vitro. Neurosci. Lett. 322:121.
8. Heneka M.T., E. Galea, V. Gavriluyk, L. Dumitrescu-Ozimek, J. Daeschner, M.K. O'Banion, G. Weinberg, T. Klockgether and D.L. Feinstein. 2002. Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22:2434.
9. Richartz-Salzburger E., A. Batra, E. Stransky, C. Laske, N. Köhler, M. Bartels, G. Buchkremer and S. Klaus. 2006. Altered lymphocyte distribution in Alzheimer's disease. J. Psychiatr. Res. 41:174.
10. Schenk D., R. Barbour, W. Dunn et al. 1999. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 400:173.
11. Dodart J.C., K.R. Bales, K.S. Gannon, S.J. Greene, R.B. DeMattos, C. Mathis, C.A. DeLong, S. Wu, X. Wu, D.M. Holtzman and S.M. Paul. 2002. Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model. Nat. Neurosci. 5:452.
12. Schenk D. 2003. Immunization against Alzheimer's disease and other neurodegenerative disorders. D. Selkoe and Y. Christen, ed. Springer-Verlag New York Inc. New York, p. 130.
13. Peterson D.A., R.J. DiPaolo, O. Kanagawa and E.R. Unanue. 1999. Quantitative analysis of the T cell repertoire that escapes negative selection. Immunity 11:453.
14. Janeway C.A. Jr. 1999. T cell development: a role for self-peptides in positive selection. Curr. Biol. 9: 342.
15. Schwartz M. and I.R. Cohen. 2000. Autoimmunity can benefit self-maintenance. Immunol. Today 21: 265.
16. Apostolou I., A. Sarukhan, L. Klein and H. von Boehmer. 2002. Origin of regulatory T cells with known specificity for antigen. Nat. Immunol. 3:756.
17. Becher B., A. Prat and J.P. Antel. 2000. Brain-immune connection: immuno-regulatory properties of CNS-resident cells. Glia 29:293.
18. Gaskin G.F., J. Finley, Q. Fang, S. Xu and S.M. Fu. 1993. Human antibodies reactive with β-amyloid protein in Alzheimer's disease. J. Exp. Med. 177:1181.
19. Monsonego A., V. Zota, A. Karni, J.J. Krieger, A. Bar-Or, G. Bitan, A.E. Budson, R. Sperling, D.J. Selkoe and H.L. Weiner. 2003. Increased T cell reactivity to amyloid β protein in older humans and patients with Alzheimer disease. J. Clin. Invest. 112:415.
20. Cole G., K.R. Dobkins, L.A. Hansen, R.D. Terry and T. Saitoh. 1988. Decreased levels of protein kinase C in Alzheimer brain. Brain Res. 452:165.
21. Govoni S., S. Bergamaschi, M. Racchi, F. Battaini, G. Binetti, A. Bianchetti and M. Trabucchi. 1993. Cytosol protein kinase C down regulation in fibroblasts from Alzheimer's disease patients. Neurology 43:2581.
22. Bosman G.J., J.H. Schuurmans Stekhoven, J.J. Melenhorst, A.J. Van Zuylen, I.G. Bartholomeus, P.J. Van Kalmthout and W.J. De Grip 1992. Are thrombocyte membranes altered in Alzheimer's disease? A morphometric and biochemicel study. Neurobiol. Aging 13:711.
23. Ligthart G.J., H.R. Schmidt and W. Hijmans. 1989. Natural killer cell function is not diminished in the healthy aged and is proportional to the number of NK cells in the peripheral blood. Immunology 68:396.
24. Aranga S., H. Kagimoto, K. Funamoko and K. Takahashi. 1991. Reduced natural killer cell activity in patients with dementia of the Alzheimer Type. Acta Neurol. Scand. 84:259.
25. Solerte S.B., M. Fioravanti, S. Severgnini, N. Cerutti, N. Pezza, M. Locatelli, F. Terenzi and E. Ferrari. 1997. Excitatory pattern of γ-interferon on natural killer cell activity in senile dementia of the Alzheimer type. Dement. Geriatr. Cogn. Disord. 8: 308.
26. Solerte S.B., M. Fioravanti, S. Severgnini, N. Cerutti, N. Pezza, M. Renzulli, M. Locatelli and E. Ferrari. 1996. Enhanced cytotoxic response of natural killer cells to IL-2 in Alzheimer's disease. Dementia 7:343.
27. Marchisio M., E. Santavenere, M. Paludi, A.R. Gaspari, P. Lanuti, A. Bascelli, E. Ercolino, A. Di Baldassarre and S. Miscia. 2005. Erythroid cell differentiation is characterized by nuclear matrix localization and phosphorylation of protein kinases C (PKC) α, δ and ζ. J. Cell. Physiol. 205:32.
28. Centurione L., C. Di Giulio, E. Santavenere, M. Cacchio, N. Sabatini, C. Rapino, G. Bianchi, M. Rapino, D. Bosco, A. Antonucci and A. Castaldi. 2005. Protein kinase C zeta regulation of hypertrophic and apoptotic events occurring during rat neonatal heart development and growth. Int. J. Immunopathol. Pharmacol. 18:49
29. Nishizuka Y. 1995. Protein kinase C and lipid signalling for sustained cellular responses. FASEB J. 9:484.
30. Becker K.P. and Y.A. Hannun. 2005. Protein kinase C and phospholipase D: intimate interactions in intracellular signaling. Cell. Mol. Life Sci. 62: 1448.
31. Goodnight J., H. Mhishak, W. Kolch and F. Mushinski. 1995. Immunocytochemical localization of eight protein kinase C isoenzyme overexpressed in NIH 3T3 fibroblasts. J. Biol. Chem. 270:9991.
32. Irie K., Y. Nakagawa and H. Ohigashi. 2005. Toward the development of new medicinal leads with selectivity for protein kinase C isozymes. Chem. Rec. 5:185.
33. Matsushima H., S. Shimohama, M. Chachin, T. Taniguchi and J. Kimura. 1996. Ca2+-dependent and Ca2+-independent protein kinase C changes in the brain of patients with Alzheimer's disease. J. Neurochem. 67:317.
34. Marchisio M., V. Bertagnolo, P. Lanuti, A.R. Gaspari, M. Paludi, F. Ciccocioppo, E. Ercolino, A. Bascelli, A. Castaldi and S. Miscia. 2006. Nuclear protein kinase C-delta: a possible checkpoint of cell cycle progression. Int. J. Immunopathol. Pharmacol. 19:287.
35. Bertagnolo V., F. Brugnoli, M. Marchisio, C. Celeghini, C. Carini and S. Capitani. 2004. Association of PI 3-K with tyrosine phosphorylated Vav is essential for its activity in neutrophil-like maturation of myeloid cells. Cell. Signal. 16:423.
36. Lee W., J.H. Boo, M.W. Jung, S.D. Park, Y.H. Kim, S.U. Kim and I. Mook-jung. 2003. Amyloid beta peptide directly inhibits PKC activation. Mol. Cell. Neurosci. 26:221.
37. Giovannini M.G., C. Scali, C. Prosperi, A. Bellucci, G. Pepeu and E. Casamenti. 2003. Experimental brain inflammation and neurodegeneration as model of Alzheimer's disease: protective effects of selective COX-2 inhibitors. Int. J. Immunopathol. Pharmacol. 16:31.
38. Kempuraj D., A. Konstantinidou, P. Boscolo, F. Ferro, M. Di Giannantonio, C.M. Conti, D. Merlitti, C. Petrarca, M.L. Castellani, R. Doyle and T.C. Theoharides. 2004. Cytokines and the brain. Int. J. Immunopathol. Pharmacol. 17:229.
39. Olariu A., K. Yamada and T. Nabeshima. 2005. Amyloid pathology and protein kinase C (PKC): possible therapeutics effects of PKC activators. J. Pharmacol. Sci. 97:1.
40. Varterasian M.L., R.M. Mohammad, M.S. Shurafa, K. Hulburd, P.A. Pemberton, D.H. Rodriguez, V. Spadoni, D.S. Eilender, A. Murgo, N. Wall, M. Dan and A.M. Al-Katib. 2000. Phase II trial of bryostatin1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Clin. Cancer Res. 6:825.
41. Bebchuk J.M., C.L. Arfken, S. Dolan-Manji, J. Murphy, K. Hasanat and H.K. Manji. 2000. A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiatry 57:95.